Overview
Net loss for Q3 widened to $7.2 mln, driven by increased R&D expenses
Company anticipates pivotal trial results for laromestrocel in 2026, potential BLA submission in 2027
Result Drivers
REVENUE DECLINE - Decrease in revenue driven by reduced demand for Bahamas Registry Trial and contract manufacturing services
R&D EXPENSES - Increase in R&D expenses due to higher personnel costs and technology transfer activities
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 EPS | -$0.39 | ||
Q3 Net Income | -$7.22 mln | ||
Q3 Gross Profit | $125,000 | ||
Q3 Income from Operations | -$7.31 mln | ||
Q3 Operating Expenses | $7.43 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Longeveron Inc is $7.00, about 88.1% above its November 3 closing price of $0.83
Press Release: ID:nGNX71nh4V
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)